CLEC9A and infection: In this respect, antigens delivered via antibodies to CLEC9A, a recently discovered C-type lectin receptor which is selectively expressed by CD141+ myeloid DCs, were shown to be a promising strategy to efficiently induce immunity against infections and malignant diseases [74, 75].